The purpose of this feature is to heighten awareness of specific adverse drug 
reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs 
to the US Food and Drug Administration's (FDA's) MedWatch program 
(800-FDA-1088). If you have reported an interesting, preventable ADR to 
MedWatch, please consider sharing the account with our readers. Write to Dr. 
Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 
215-707-4936; e-mail: mmancano@temple.edu). Your report will be published 
anonymously unless otherwise requested. This feature is provided by the 
Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's 
MedWatch program and Temple University School of Pharmacy. ISMP is an FDA 
MedWatch partner.